AUTHOR=Tang Lingfeng , Li Zhenghang , Jiang Linshan , Shu Xiujie , Xu Yingkun , Liu Shengchun 

TITLE=Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.999716

DOI=10.3389/fonc.2022.999716

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>To characterize the clinicopathological features and evaluate the neoadjuvant chemotherapy (NACT) efficacy of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer.</p></sec><sec><title>Methods</title><p>A total of 905 breast cancer patients who received 4 cycles of thrice-weekly standard NACT in the First Affiliated Hospital of Chongqing Medical University were retrospectively enrolled, including 685 cases with HER2-low expression and 220 cases with HER2-negative expression. Clinicopathological features were compared between patients with HER2-negative and HER2-low expression. Univariate and multivariate logistic regression analyses were used to find the independent factors of achieving a pathological complete response (pCR) after NACT.</p></sec><sec><title>Results</title><p>There were significant differences in stage_N (<italic>P</italic> = 0.014), histological grade (<italic>P</italic> = 0.001), estrogen receptor (ER) status (<italic>P</italic> &lt; 0.001), progesterone receptor (PgR) status (<italic>P</italic> &lt; 0.001), NACT regimens (<italic>P</italic> = 0.032) and NACT efficacy (<italic>P</italic> = 0.037) between patients with HER2-negative and HER2-low expression breast cancer. In subgroup analysis, histological grade (<italic>P</italic> = 0.032), ER (<italic>P</italic> = 0.002), Ki-67 (<italic>P</italic> &lt; 0.001) and HER2 status (<italic>P</italic> = 0.025) were independent predictors of achieving a pCR in ER-positive breast cancer. And the nomogram for pCR in ER-positive breast cancer showed great discriminatory ability with an AUC of 0.795. The calibration curve also showed that the predictive ability of the nomogram was a good fit to actual observations. Then, in the analysis of ER-negative breast cancer, only stage_N (<italic>P</italic> = 0.001) and Ki-67 (<italic>P</italic> = 0.018) were independent influencing factors of achieving a pCR in ER-negative breast cancer.</p></sec><sec><title>Conclusion</title><p>HER2-low breast cancer was a different disease from HER2-negative breast cancer in clinicopathological features. Moreover, the NACT efficacy of HER2-low breast cancer patients was poorer.</p></sec>